Nelfinavir in-vitro study reported that Nelfinavir inhibits replication of SARS-CoV-2 of EC 50 = 1.13 µM the same study reported Amprenavir to have inhibition of EC 50 = 31.32 µM and reported Indinavir to have EC 50 = 59.14 µM . This ranking of nelfinavir first results disagrees with both the docking results and the PocketMatch results. The design of this study makes it incapable of ranking binding of similar compounds. As for the docking, this is expected general docking isn't very accurate, and for the PocketMatch results we can't use the similarity of pockets to rank molecules that bind to the same binding site because the site change form structure to structure due to the state the structure was crystalized on, and the fact that the binding site change shape to accommodate the ligand (induced-fit theory). However, it's an excellent method to capture potential molecules. All of them works on ADP RIBOSE PHOSPHATASE (Nsp 3). Recently the WHO discontinued the hydroxychloroquine and lopinavir/ritonavir treatment arm , from the results of this study and the finding of nelfinavir study, I suggest the combination Nelfinvir/Ritonavir as an alternative to lopinavir/ritonavir.